Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for hard-to-treat stomach and bowel cancers

NCT ID NCT05104567

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called SAR444245 combined with other cancer treatments in 138 adults with advanced gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancer. The goal was to see if the combination could shrink tumors. The study is complete, and results will help determine if this approach is effective for patients who have not responded to standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus colorectal cancer colorectal neoplasm esophageal adenocarcinoma esophageal squamous cell carcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER GASTRIC CANCER HEPATOCELLULAR CARCINOMA OESOPHAGEAL ADENOCARCINOMA OESOPHAGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

  • AdventHealth Orlando Site Number : 8400005

    Orlando, Florida, 32804, United States

  • City of Hope Site Number : 8400007

    Duarte, California, 91010, United States

  • Investigational Site Number : 0560001

    Leuven, 3000, Belgium

  • Investigational Site Number : 0560002

    Brussels, BE-1200, Belgium

  • Investigational Site Number : 0560003

    Edegem, 2650, Belgium

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, 8420383, Chile

  • Investigational Site Number : 1560002

    Wuhan, 430022, China

  • Investigational Site Number : 2500001

    Villejuif, 94800, France

  • Investigational Site Number : 2500002

    Paris, 75015, France

  • Investigational Site Number : 2500004

    Bordeaux, 33075, France

  • Investigational Site Number : 2500005

    Poitiers, 86021, France

  • Investigational Site Number : 2500006

    Brest, 29200, France

  • Investigational Site Number : 3800001

    Rozzano, Lombardy, 20089, Italy

  • Investigational Site Number : 3800002

    Milan, 20133, Italy

  • Investigational Site Number : 3800003

    Milan, 20132, Italy

  • Investigational Site Number : 4100001

    Seoul, Seoul-teukbyeolsi, 05505, South Korea

  • Investigational Site Number : 4100002

    Seoul, Seoul-teukbyeolsi, 03080, South Korea

  • Investigational Site Number : 4100003

    Seoul, Seoul-teukbyeolsi, 06351, South Korea

  • Investigational Site Number : 4100004

    Seoul, Seoul-teukbyeolsi, 03722, South Korea

  • Investigational Site Number : 5280001

    Amsterdam, 1081 HV, Netherlands

  • Investigational Site Number : 5280003

    Rotterdam, 3015 GD, Netherlands

  • Investigational Site Number : 7240001

    Pamplona, Navarre, 31008, Spain

  • Investigational Site Number : 7240002

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number : 7240003

    Madrid / Madrid, Madrid, Comunidad de, 28007, Spain

  • Investigational Site Number : 7240004

    Madrid / Madrid, Madrid, Comunidad de, 28050, Spain

  • Investigational Site Number : 7240005

    Santander, Cantabria, 39008, Spain

  • Investigational Site Number : 7240006

    Barcelona, Barcelona [Barcelona], 08036, Spain

  • Investigational Site Number : 7240101

    Madrid, Madrid, Comunidad de, 28027, Spain

  • Seattle Cancer Care Alliance Site Number : 8400009

    Seattle, Washington, 98115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.